Categories
Blog GRAS

How the GRAS Process Differs for Human Food and Animal Feed

GRAS process comparison for human food and animal feed

When introducing a new substance into the market, one of the first questions you need to answer is whether it’s intended for human food or animal feed. This decision significantly impacts how the substance must be evaluated and documented under the GRAS (Generally Recognized as Safe) process. 

The regulatory pathway for GRAS differs depending on the target consumer. Human food GRAS notifications follow one route, while animal feed submissions involve added layers, including nutritional utility and environmental considerations. 

In this post, we’ll focus on the key differences between GRAS for human food and for animal feed, and how to ensure your submission is complete, compliant, and ready for review. Keep reading to learn more 

What is the GRAS process? 

The GRAS process allows companies to determine that a substance is safe for its intended use without submitting a full food additive petition to the FDA. Here’s how it works: 

  • For human food, a company can independently determine GRAS status with support from a panel of qualified experts. Once determined, the ingredient can be marketed without formal FDA approval. 
  • For animal feed, the process is more complex. In addition to the voluntary GRAS notification: 
  • Federal review is often required. 
  • Companies may need to file a feed additive petition. 
  • Some products may require an AAFCO ingredient definition. 
  • Others might go through the newer FDA Animal Feed Ingredient Consultation (AFIC) process. 

Each pathway depends on the ingredient’s intended use and the regulatory landscape it falls under. 

Comparing the human food vs. animal feed GRAS process 

At a glance, GRAS submissions for human food aim to prove general safety, while those for animal feed must demonstrate both safety and nutritional utility for specific species. If the ingredient is used in food-producing animals, human safety must also be considered. 

Human food GRAS notices are reviewed by the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), focusing on toxicology, dietary exposure, and historical use. They are usually transparent and less likely to involve redacted data. 

Animal feed GRAS notices go to the Center for Veterinary Medicine (CVM). These require deeper data sets, such as species-specific nutrition profiles, stability testing within feed, and sometimes environmental impact assessments. 

To help visualize these differences, the chart below outlines the main distinctions between the two GRAS pathways. 

GRAS Component Human Food Animal Feed 
FDA Review Center CFSAN CVM 
Primary Focus General safety for human population Species-specific safety and nutritional utility 
Data Transparency Mostly public with minimal redactions Often includes redacted proprietary data 
Nutritional Requirements Not always emphasized Must match AAFCO nutrient profiles 
Stability Testing Ingredient as packaged Ingredient within feed matrix and homogeneity required 
Dietary Exposure Assessment Based on national food survey data Based on average daily feed intake by species 
Environmental Assessment Not typically required Often required, especially for livestock feed 
Residue and Human Safety Not applicable Required for food-producing animals 
Regulatory Complexity Single federal pathway Federal and state layers (AAFCO, AFIC) 

Key differences in GRAS submissions 

The differences between human food and animal feed GRAS submissions go beyond just who consumes the product. They span areas like safety requirements, confidentiality, labeling, dietary exposure, and environmental impact. Below, we outline these distinctions in more detail. 

1. Use-specific safety requirements

The GRAS process is centered on intended use, not just the ingredient itself. A substance that is GRAS for human consumption may not automatically qualify as GRAS for animal feed. Intended species, dosage, and method of consumption all influence the FDA’s evaluation. 

2. Confidentiality and data presentation

Human food GRAS notifications typically include summaries of manufacturing steps and high-level safety evidence. These are often publicly accessible with little redacted content. In contrast, animal feed submissions frequently contain confidential data, such as detailed Certificates of Analysis and proprietary manufacturing information. 

3. Composition and labeling needs

Animal feed GRAS notices must include specific nutritional information like crude protein, fiber, and fat. This helps manufacturers comply with species-based dietary requirements and labeling standards set by AAFCO. Such detail is less common in human food GRAS submissions. 

4. Safety and stability testing

Both types of GRAS submissions require supporting safety data, including toxicology and genotoxicity studies. For animal feed, this data must confirm safety in the target species. If the ingredient is intended for food-producing animals, the analysis must also address potential human exposure through animal products. 

Animal feed submissions must also show that the ingredient remains stable in feed formulations and is evenly distributed. These factors help ensure consistent nutrient delivery across all servings. 

5. Dietary exposure estimates

For human food, dietary exposure is calculated using national data to determine both average and high-end consumption. Animal feed exposure estimates are simpler, relying on average feed intake data for each species. 

If an ingredient is used in livestock feed, its impact on human consumers must also be factored in. This includes evaluating potential residues in milk, eggs, or meat. 

6. Environmental and utility considerations

Environmental assessments are typically required for animal feed ingredients, especially if the ingredient or its byproducts may enter soil or water systems. These are generally not required for human food GRAS submissions. 

In addition, animal feed GRAS submissions must demonstrate utility. That means showing that the ingredient provides real nutritional or functional value to the animal. If it’s promoted as a source of omega-3s, for example, the data must confirm bioavailability. 

Need help navigating the GRAS process? 

Whether you’re preparing a GRAS notification for human food or animal feed, the regulatory requirements can be complex. At Quality Smart Solutions, our team of regulatory experts is here to guide you every step of the way, from manufacturing data to safety studies to dietary exposure assessments. 

Contact us today to ensure your next submission is accurate, complete, and aligned with FDA expectations. 

Categories
Blog Cosmetics

Traditional cosmetics vs. cosmeceuticals: What’s the difference? 

Comparison chart showing traditional cosmetics and cosmeceutical

Understanding the distinction between traditional cosmetics vs. cosmeceuticals is essential if you’re manufacturing or marketing skincare or beauty products in North America. While both types of products may appear similar on store shelves, they follow different regulatory pathways, and that has a direct impact on your compliance obligations. 

Whether you’re selling moisturizers, anti-aging serums, or acne treatments, knowing how your product is classified under Health Canada and the FDA can help you avoid costly enforcement issues, delays at customs, or claims that mislead consumers.  

Keep reading to learn how these categories differ, and what that means for your compliance strategy. 

What are traditional cosmetics?

In both Canada and the United States, traditional cosmetics are products intended to cleanse, beautify, or alter the appearance of the body without affecting its structure or function. These products do not claim to treat or prevent any disease and are not meant to alter bodily functions. 

Here’s a quick comparison of how traditional cosmetics are defined by regulators: 

Regulatory Body Definition Examples 
Health Canada Any substance used to cleanse, improve, or alter the complexion, skin, hair, or teeth. Lipstick, body lotion, perfume 
FDA (U.S.) Products intended for cleansing, beautifying, promoting attractiveness, or altering appearance without affecting the body’s structure or functions. Shampoo, deodorant, makeup, nail polish 

Both agencies emphasize that products making only cosmetic claims (not therapeutic ones) generally fall into the traditional cosmetic category. Here are some additional insights: 

  • Health Canada defines a cosmetic as “any substance or mixture of substances manufactured, sold or represented for use in cleansing, improving or altering the complexion, skin, hair or teeth.”  
  • The FDA defines cosmetics similarly, but draws a stricter line between cosmetics and drugs. If your product makes therapeutic claims or affects the body’s structure/function, it may be regulated as a drug or both a cosmetic and drug. 

So, while makeup, shampoo, and moisturizers typically qualify as cosmetics, the moment a claim suggests treatment, healing, or bodily alteration, the classification (and even compliance path) can change significantly. 

What are cosmeceuticals?

Cosmeceuticals are often marketed as a hybrid between cosmetics and pharmaceuticals. They typically include active ingredients like peptides, retinoids, or alpha hydroxy acids that promise to improve skin health or provide anti-aging effects. 

However, here’s the catch, the term “cosmeceutical” is not officially recognized by either Health Canada or the FDA. This can create confusion, especially for businesses using the term in branding or advertising. 

In Canada, if a product makes therapeutic or drug-like claims (e.g., “reduces wrinkles” or “treats acne”), it may be regulated as a drug or a natural health product (NHP) and require additional licensing, such as a DIN or NPN. 

In the U.S., products making similar claims may fall under drug regulations, and companies must follow drug labelling and premarket approval requirements. 

Key compliance risks when misclassifying cosmeceuticals

Marketing a cosmeceutical with claims that go beyond cosmetic purposes could trigger regulatory action. These are some of the most common pitfalls: 

  • Unapproved therapeutic claims: Phrases like “heals skin” or “stimulates collagen” can reclassify your product as a drug. 
  • Missing licences: In Canada, NHPs require a product licence and a site licence. 
  • Incorrect labelling: Your product label must reflect its classification, including specific disclosures, ingredient lists, and usage instructions. 
  • Non-compliant advertising: Promoting cosmetic products with exaggerated benefits can be flagged by regulators in both countries. 

How to ensure compliance with your product 

If you’re unsure whether your product is a cosmetic, NHP, or drug, it’s important to assess your ingredients, claims, and format. Working with a regulatory partner like Quality Smart Solutions can help you navigate classification, licensing, and labelling requirements in Canada and the U.S. 

Here’s how we can support you: 

  • Regulatory classification and risk assessment 
  • Cosmetic Notification Form (CNF) submission in Canada 
  • NPN or DIN applications for therapeutic claims 
  • FDA cosmetic registration and ingredient safety 
  • Label and claims review based on product type 

Curious about how to stay compliant in both markets? Check out our tailored solutions for Canada and the U.S. under MoCRA to see how we can support your product’s success. 

Final thoughts

When it comes to traditional cosmetics vs. cosmeceuticals, the difference isn’t just in the formula, it’s in the regulatory pathway. Using the wrong classification can expose your business to fines, recalls, or costly delays. 

If you’re unsure how your product is classified or need help getting compliant, we’re here to support you. Contact us to schedule a free consultation and ensure your products are ready for market. 

Categories
Blog Regulatory Compliance

What Is an SFCR Importer of Record?

SFCR importer of record explanation for Canadian food imports

If you’re importing food into Canada, one of the key roles you’ll need to understand is that of the SFCR importer of record. This designation comes with specific responsibilities under the Safe Food for Canadians Regulations (SFCR), and getting it right is essential for avoiding compliance headaches. 

But there’s more to it now. The Canada Border Services Agency (CBSA) has introduced a new system called CARM, which stands for CBSA Assessment and Revenue Management initiative. It’s designed to modernize how duties and taxes are collected, and it’s changing how businesses interact with CBSA. From registering online to posting security and submitting declarations, CARM is now a critical piece of the import process. 

In this blog, we’ll explain what an SFCR importer of record does, how CARM fits in, and what steps you need to take to stay compliant and avoid delays. Let’s dive in. 

Understanding the SFCR importer of record 

The SFCR importer of record is the entity legally responsible for ensuring that imported food products meet the Safe Food for Canadians Regulations (SFCR) and other applicable laws. This includes holding the correct food import licence, maintaining traceability records, and ensuring food safety standards are met. 

Under the SFCR, most businesses importing food for commercial sale must obtain a licence issued by the Canadian Food Inspection Agency (CFIA). This requirement applies whether you’re a distributor, broker, or manufacturer. The licence confirms your business is authorized to import food into Canada and that it maintains the necessary traceability and food safety systems. 

Whoever acts as the importer of record, whether it’s your business or a designated partner like Quality Smart Solutions, is accountable for the accuracy of customs declarations and the proper classification of goods. You can find detailed information about licensing eligibility, conditions, and the application process on the CFIA’s official food licence page. 

What is CARM and how does it affect food importers? 

CARM, or the CBSA Assessment and Revenue Management system, is a new digital platform being phased in to streamline importation processes. Once fully implemented, CARM will require all importers, including food importers, to: 

  • Register their business in the CARM Client Portal 
  • Post financial security (such as a surety bond) 
  • Pay duties and taxes directly through the portal 
  • Classify goods and manage accounting declarations online 

This means that the SFCR importer of record will now have greater responsibility in digital declarations and financial accountability. It also adds urgency to ensuring you have the right partners and systems in place. 

For details on the CARM initiative, visit CBSA’s official CARM page.

Why accurate classification and licensing matters 

Being an SFCR importer of record isn’t just a box to check. Misclassifying goods, skipping licensing, or failing to register properly in CARM could result in: 

  • Import delays or refusals at the border 
  • Administrative Monetary Penalties (AMPs) 
  • Suspension or cancellation of your import privileges 

That’s why many businesses choose to work with regulatory experts to ensure everything is done correctly the first time. 

How regulatory experts can support you 

At Quality Smart Solutions, we help importers simplify the licensing process and avoid regulatory pitfalls. Whether you’re applying for your SFCR licence, adjusting your operations for CARM, or preparing documentation, our team is ready to guide you. 

You don’t need to navigate this alone. We offer tailored compliance solutions so you can focus on growing your business without worrying about setbacks at the border. 

We offer SFCR Food Licence Services designed to help you meet all regulatory requirements with clarity and confidence. Need help now? Contact us for a free consultation. 

 

Categories
Blog Medical Devices

How to Navigate MDL and MDEL Licensing in Canada

MDL vs MDEL explained for Health Canada compliance

If you’re planning to sell or distribute a medical device in Canada, you’re going to hear two terms over and over again: MDL and MDEL. Understanding the difference between them is one of the first steps toward compliance with Health Canada’s medical device regulations. 

The two licences cover different parts of the process. One applies to the product itself, the other to your business. And if you get them mixed up or apply too late, you could face delays, inspection issues, or even enforcement actions. 

In this guide, you’ll learn what MDL and MDEL mean, how they apply to your operations, and how to meet Health Canada’s requirements. Whether you’re a new entrant to the Canadian market or looking to stay on track during annual renewals, this is a resource you can come back to. 

What is MDL? 

MDL stands for Medical Device Licence. This licence is issued by Health Canada to manufacturers of Class II, III, and IV medical devices. It gives formal authorization to sell those products in the Canadian market. 

To apply for an MDL, manufacturers must submit a detailed application that includes evidence related to safety, efficacy, and quality. This might involve clinical data, product testing results, and manufacturing process documentation. Health Canada reviews this information to ensure the device meets applicable standards before granting approval. 

Device classes are assigned based on risk. Class I devices pose the lowest risk and don’t require an MDL. Class II devices (e.g. contact lenses), Class III devices (e.g. ventilators), and Class IV devices (e.g. pacemakers) each require progressively more rigorous oversight. 

Once an MDL is issued, the manufacturer is expected to monitor post-market performance, report any incidents, and apply for amendments if the product is modified. 

What is MDEL? 

MDEL stands for Medical Device Establishment Licence. While the MDL is about the product, the MDEL is about the business handling that product. It applies to importers and distributors of medical devices, regardless of class. 

An MDEL shows that your business follows proper protocols for complaint handling, product recalls, storage, distribution, and recordkeeping. It’s designed to ensure that even if a company isn’t the manufacturer, it still has systems in place to protect end users. 

Unlike the MDL, which only needs to be updated when product details change, the MDEL must be renewed annually. Health Canada may conduct inspections to assess whether your quality management system and compliance practices are in place and functioning. 

Even if you deal only in Class I devices, like simple thermometers or bandages, you still need an MDEL if you’re importing or distributing them in Canada. 

Why both licences matter 

MDL and MDEL are distinct but connected. Health Canada requires that anyone involved in the medical device supply chain is traceable and accountable. This means that both the product itself and the company handling it must be reviewed and authorized. 

Failing to hold the correct licence can result in delays at customs, rejection of products, or more serious enforcement actions. For example, a foreign manufacturer trying to ship Class III devices into Canada without an MDL will not be allowed to sell.  

Similarly, a Canadian importer without an MDEL may face seizure of goods or facility inspection warnings. 

Key differences between MDL and MDEL 

MDL (Medical Device Licence) 

MDEL (Medical Device Establishment Licence) 

Required for Class II, III, IV devices 

Required for importers and distributors 

Applies to the product 

Applies to the business 

Requires safety and quality documentation 

Requires operational compliance procedures 

Valid unless cancelled or amended 

Must be renewed annually 

Reviewed by the Medical Devices Directorate 

Overseen by Health Canada’s ROEB 

Do you need both? 

Some companies only need one of the two. For example, a Class I device distributor in Canada only needs an MDEL. A foreign manufacturer of a Class III device only needs an MDL. But many companies need both. 

Let’s say you manufacture a Class II diagnostic device overseas and plan to import and sell it in Canada through your local office. You would need: 

  • An MDL for the device itself 
  • An MDEL for your Canadian establishment 

This scenario is common for global companies with regional offices. It’s also relevant to Canadian manufacturers that manage their own distribution in-house. 

Staying compliant year-round 

Holding the correct licence is not enough. You must maintain your compliance through proper documentation, training, and reporting practices. Here are some best practices: 

  • Keep records of all sales, complaints, and distribution for at least five years 
  • Maintain clear procedures for recalls and customer feedback 
  • Ensure your staff are trained on Health Canada requirements 
  • Report incidents or changes in business operations promptly 
  • Submit your MDEL renewal application before the deadline each year 

Health Canada publishes inspection summaries and issues warning letters when businesses fail to comply. Staying organized and proactive can help you avoid those outcomes. 

Where to get help 

The application process for MDL and MDEL can be complex, especially if you’re new to the Canadian market or working with limited internal resources. That’s where third-party regulatory consultants like Quality Smart Solutions can make a big difference. 

We’ve helped hundreds of companies prepare, submit, and maintain their medical device licences. Our team knows how to navigate the forms, gather the right documentation, and respond to regulatory questions. 

Contact us to get expert guidance or request a consultation. You can also visit Health Canada’s Medical Devices page for official resources and application guidelines. 

Disclaimer: This content is for informational purposes only and does not constitute legal or regulatory advice. 

Categories
Blog GRAS

Struggling With GRAS Compliance? Here’s What to Do

GRAS compliance checklist with FDA guidance

If you’re finding it difficult to navigate the GRAS process, you’re not alone. Whether you’re introducing a new food ingredient or formulating a novel product, understanding what it takes to meet GRAS standards can feel overwhelming. The FDA has outlined specific requirements, but without a clear plan, your submission might face delays or even rejection. 

In this guide, we’ll explain what GRAS status means, how to determine if your ingredient qualifies, and what actions you can take to move forward with confidence. If you’re unsure about the next step, this article will give you the clarity and direction you need. 

What does GRAS mean? 

GRAS stands for “Generally Recognized as Safe.” It’s a designation used by the FDA to confirm that a food ingredient is considered safe under the conditions of its intended use. According to the FDA, ingredients can achieve GRAS status through: 

  • Scientific procedures based on publicly available safety data and peer-reviewed research 
  • Common use in food prior to 1958, with a long history of safe consumption 

To meet these requirements, the evidence supporting an ingredient’s safety must be widely accepted by qualified experts and properly documented. If your ingredient doesn’t meet this standard, a food additive petition may be required instead. 

Self-affirmation or FDA notification? 

There are two main routes you can take to establish GRAS status: 

  1. Self-affirmed GRAS – You collect the data, prepare a safety dossier, and conclude internally that the ingredient is safe. No FDA review is required. 
  2. GRAS Notification – You formally notify the FDA and submit supporting documentation. The agency reviews your submission and responds with a letter, either stating they have no questions or requesting additional details. 

While self-affirmation gives you control over the process, many companies choose notification to build consumer trust and minimize regulatory risk. 

Where things can go wrong 

Even with solid scientific data, achieving GRAS status isn’t always smooth. Some common issues include: 

  • Incomplete or outdated safety data 
  • Poorly organized dossiers 
  • Limited consensus from qualified experts 
  • Gaps in toxicology or dietary exposure assessments 

Following the FDA’s expectations closely and ensuring all your documentation is current and thorough is key to moving forward successfully. 

What to do if you’re facing roadblocks 

If you’re encountering challenges with GRAS requirements, here are some practical next steps: 

1. Evaluate your ingredient carefully

Make sure your ingredient is eligible. Does it have a well-documented history of safe use? Is there reliable, peer-reviewed safety data available? 

2. Get expert support

Working with experienced consultants can make the process more efficient and reduce the risk of missteps. At Quality Smart Solutions, we help businesses build strong dossiers and prepare GRAS notifications that align with FDA standards. Contact us to learn more. 

3. Stay current on FDA guidelines

Regulatory expectations evolve. Be sure your data and approach match the FDA’s most up-to-date GRAS procedures. You can find the latest information on the FDA’s GRAS page. 

4. Be ready for audits

Even if you pursue self-affirmation, your records should be audit-ready. This includes safety studies, expert opinions, and all relevant documentation. 

Let’s get your GRAS journey on track 

GRAS is more than a checkbox. It’s the foundation for getting your product market-ready while earning consumer trust. At Quality Smart Solutions, we offer tailored support to help you move forward with clarity and confidence. Whether you’re drafting a self-affirmed GRAS dossier, submitting a GRAS notification to the FDA, or preparing for audits, our team is ready to assist. We also support: 

  • Toxicology assessments 
  • Literature reviews and safety data analysis 
  • Expert panel coordination 
  • Regulatory strategy and communication with FDA 

To explore the full range of our GRAS services, visit our GRAS Notification page. 

If you’re unsure where to start or need help refining your submission, let’s talk. Fill out our contact form to book a free consultation with one of our regulatory experts. We’ll help you chart the right path, without the guesswork. 

Categories
Food Safety News

FDA Approves Natural Food Colors for Safer Use

Natural food colors approved by FDA for use in various food categories

The FDA has officially approved three new food color additives derived from natural sources. These offer a safer alternative to petroleum-based dyes in the U.S. food supply. The approval of these natural food colors marks a big step toward cleaner labeling and healthier food options.

Moreover, this update supports the U.S. Department of Health and Human Services’ plan to phase out synthetic dyes. As part of its Make America Healthy Again campaign, the FDA is acting in response to growing demand for transparent, natural ingredients. Keep reading to learn how these newly approved colors may affect your product formulations.

What are the newly approved natural food colors?

The three FDA-approved natural color additives are: 

  • Galdieria extract blueThis blue colorant comes from red algae. It is now allowed in many products, including beverages, yogurts, smoothies, candies, cereals, dairy desserts, and whipped toppings. Fermentalg, a French biotechnology company, submitted the petition.
  • Butterfly pea flower extract: Already added to several food and drink products, its use now includes snacks like chips, cereals, and pretzels. The extract provides blue, purple, or green hues. U.S.-based Sensient Colors LLC submitted this petition. 
  • Calcium phosphate: This white colorant is now approved for ready-to-eat chicken, candy coatings, and powdered sugars. Innophos Inc. in New Jersey filed the petition. 

These approvals are especially impactful for brands seeking to eliminate artificial additives while maintaining visual appeal in their food products. 

Why this matters for your compliance strategy

Under U.S. law, manufacturers must get FDA approval before using color additives in food. This means your team needs to confirm that any new ingredient is used only in approved ways. Once approved, the colors are available for any company to use.

In addition, the FDA’s decision also signals a faster review process for future color additive petitions. According to FDA Commissioner Dr. Martin Makary, the agency is committed to expediting approvals to support a nationwide shift to safer ingredients. 

Staying ahead of regulatory change 

If your products currently use petroleum-based dyes, now is the time to start planning your transition. Reformulating with FDA-approved natural food colors not only enhances your brand’s marketability but also helps you stay ahead of potential restrictions or consumer backlash. Consider reviewing your ingredient lists and labels to determine whether your formulations may benefit from this regulatory update. 

At Quality Smart Solutions, we can support you with end-to-end regulatory services, from formulation review and label compliance to guidance on FDA submissions and ingredient approvals. Need help transitioning to natural food colorants? Contact us today to speak with our food compliance experts. 

Sources: U.S. FDA Press Release on Food Colors 

Categories
News Regulatory Updates

FDA Unannounced Inspections: What Foreign Manufacturers Need To Know 

FDA conducting surprise inspection at foreign manufacturing facility

FDA unannounced inspections are no longer limited to U.S. facilities. The U.S. Food and Drug Administration (FDA) recently announced an expansion of its unannounced inspection program to now include foreign manufacturing sites. This change will directly impact companies exporting pharmaceuticals and other regulated products into the U.S.

If you rely on international partners or operate your own facilities abroad, this update could change how you prepare for inspections. Keep reading to understand the key changes, potential risks, and how to ensure you remain compliant. 

Why is the FDA expanding unannounced inspections?

The FDA wants to strengthen oversight of global supply chains. Previously, inspections at foreign sites were usually pre-announced, which gave facilities time to prepare. However, reports of quality issues and falsified records abroad led the FDA to act. By reducing advance notice and increasing surprise visits, the agency hopes to observe day-to-day operations more accurately.

This change supports the FDA’s broader mission to protect product quality and patient safety. Because more than 70% of active pharmaceutical ingredients and many finished drugs come from outside the U.S., stronger foreign oversight is essential.

What does this mean for your business? 

If your supply chain includes foreign manufacturers, your business could feel the impact. A non-compliant facility abroad may trigger delays, import holds, or even product recalls. These outcomes can damage your brand and reduce revenue.

For companies with foreign operations, the biggest shift is the need for constant inspection readiness. Relying on advance notice is no longer safe. FDA unannounced inspections can happen at any time. If your operations fail to demonstrate consistent quality practices during a surprise visit, your company may face Form 483 observations or even stricter enforcement.

How to stay compliant

The key to managing this change is maintaining constant inspection readiness. Here’s how you can prepare: 

  • Strengthen your quality management system (QMS): Ensure your procedures are documented, up to date, and aligned with U.S. FDA expectations. 
  • Train staff regularly: Your team should understand their roles during inspections and how to respond professionally and accurately. 
  • Conduct internal audits: Regular reviews can help identify and fix gaps before the FDA does. 
  • Review supplier agreements: If you outsource manufacturing, make sure your partners are held to the same quality standards and are also prepared for unannounced inspections. 

Working with a regulatory partner can help you stay ahead of these requirements. At Quality Smart Solutions, we support companies with inspection readiness, SOP development, mock audits, and ongoing compliance strategies. 

The bottom line

The FDA’s move to expand unannounced inspections to foreign manufacturing facilities is a signal for businesses to take inspection preparedness seriously, no matter where production happens. It’s no longer a matter of if you’ll be inspected without notice, but when. 

To learn more about this update directly from the FDA, read the full press release. 

Need help preparing for potential FDA inspections or reviewing your quality systems? Contact us or fill out the form below to book a consultation with one of our regulatory experts. 

Categories
FDA News

FDA Front-of-Package Labeling Deadline Extended

FDA front-of-package labeling rule comment extension

FDA Front-Of-Package Labeling Comment Period Extended

The U.S. Food and Drug Administration has extended the comment period for its proposed rule on front-of-package labeling. Originally set to close earlier, the comment window is now open until July 15, 2025. This extension gives stakeholders additional time to evaluate the rule’s potential impact and provide meaningful feedback. 

If you manufacture, label, or distribute food products in the U.S., this proposed change could affect how your nutrition information appears on packages. Understanding what the proposed rule could mean for your products is essential for staying compliant and prepared. Read on to learn how this extension connects with broader regulatory goals.

What the proposed rule aims to do 

The FDA’s proposed rule would introduce a standardized front-of-package (FOP) nutrition labeling system designed to make key nutrition information more accessible to consumers. Specifically, it would highlight calories, saturated fat, sodium, and added sugars directly on the front of food packages. As a result, it aims to promote healthier choices at the point of purchase. 

This move supports the FDA’s broader nutrition initiative and aligns with global efforts to improve public health through clear, visible labeling. Similar systems have already been implemented in other countries, such as the UK’s traffic light labels and Chile’s warning symbols. 

Why this matters for your business 

If the rule is finalized, food companies may need to update packaging designs, supply chains, and compliance protocols. This change may improve transparency and build consumer trust. However, it could also add regulatory and operational challenges.

By submitting comments during the extended period, businesses have a unique opportunity to influence how the rule is finalized. That way, the final rule can better balance public health goals with practical implementation.

How to submit your comments 

To make your voice heard, submit comments by July 15, 2025, through Regulations.gov. Be sure to include the docket number FDA-2024-N-2910 when submitting your input. 

Whether you’re providing technical data, outlining concerns, or offering implementation suggestions, clear and concise comments will help the FDA assess the real-world impact of its proposal. 

Stay proactive with regulatory updates 

At Quality Smart Solutions, we help food businesses stay on top of evolving FDA regulations and maintain compliance across the board. Our experts can help whether you’re updating labels, planning for new packaging rules, or launching new products. 

We offer end-to-end support, from nutrition facts panels and bilingual labeling to FDA submissions and post-market updates. Contact us or fill out the form below to learn how we can help you stay ahead of regulatory changes. 

Categories
News Regulatory Updates

Health Canada electronic filing updates: Key changes in 2025

Health Canada electronic filing requirements for drug product submissions

If your team handles drug product submissions in Canada, there’s a recent update from Health Canada you might want to take a closer look at. As of April 1, 2025, new electronic filing rules are now in place for both eCTD and non-eCTD formats. 

These updates aim to make the submission process more streamlined and easier to manage on both sides. For many companies, it’s also a good opportunity to revisit internal systems, templates, and workflows. In this article, we’ll walk you through what’s changed, why it’s relevant, and how you can adapt with confidence. 

What changed in April 2025?

Health Canada released new guidance on how drug product submissions should be filed. This applies to both new submissions and those already in progress, especially if you’re using the non-eCTD format. Here’s a quick overview of the changes: 

  • Electronic-only submissions: All submissions must be sent electronically. Paper copies are no longer accepted. 
  • eCTD format now required for many product types: If you’re submitting to the Therapeutic Products Directorate (TPD) or Biologics and Genetic Therapies Directorate (BGTD), you need to use the eCTD format. 
  • Non-eCTD is still allowed for certain products: This includes natural health products and some non-prescription disinfectants, but they must now follow stricter file structure and naming rules. 
  • New validation rules: Health Canada has introduced new technical checks. If your submission doesn’t meet the formatting or structure requirements, it may be rejected immediately. 

You can read the full guidance on the Health Canada website. 

Why does this matter to you?

This isn’t just a technical update. If your tools, templates, or workflows aren’t ready for these changes, you could face: 

  • Delays in product approvals 
  • Extra costs for re-submissions 
  • Compliance issues 

If you’re still using paper-based processes or outdated file templates, now’s the time to make changes. Being proactive can help you avoid last-minute setbacks and keep your submissions moving forward. 

How to prepare for compliance

Here are five practical steps to help you adjust: 

  1. Review your current process 
    Look at how your team prepares and submits applications. Highlight areas that may need updates. 
  2. Update templates and file structures 
    Make sure your documents and folders match Health Canada’s new format and naming rules. 
  3. Use the right eCTD software 
    Choose a reliable tool that supports Health Canada’s updated validation checks. 
  4. Train your team 
    Everyone involved in submissions should be familiar with the new rules. Provide training if needed. 
  5. Ask for help if needed 
    If you’re unsure about anything, a regulatory partner can save you time and reduce risks. Contact us to see how we can support you. 

Final thoughts

Health Canada’s push for standardized electronic submissions is meant to improve review timelines and consistency. But to keep up, companies need to adjust how they prepare and submit documentation. 

Whether you’re working on an NDS, SNDS, or DIN application, it’s a good time to review your internal processes. Getting ahead of these changes helps reduce the chance of delays and compliance problems. 

Not sure how this update affects your next submission? Reach out to our regulatory experts or fill out the form below for personalized guidance. 

Categories
Blog FDA Health Canada Regulatory Compliance

Navigating FDA and Health Canada Rules for Eczema Products

FDA and Health Canada eczema compliance guide

The eczema product market continues to grow as consumer demand increases, but that doesn’t mean you can jump in without a plan. FDA and Health Canada rules for eczema products vary widely depending on the formulation and claims. Many companies risk product delays or enforcement action by misclassifying their product or using unapproved claims. 

If you’re marketing an eczema treatment in Canada or the United States, your first step is understanding whether your product is a drug, cosmetic, or natural health product (NHP). That classification affects your registration pathway, labelling requirements, and compliance obligations.  

Let’s break it down to help you choose the right path and avoid regulatory issues. Keep reading to make an informed decision. 

Product classification drives your compliance path

For both Canada and the U.S., the classification of eczema products hinges on their intended use and claims. If your product claims to treat, relieve, or prevent eczema symptoms, like inflammation, redness, or itching, it will likely be considered a drug. 

In Canada, some eczema treatments may qualify as NHPs if they contain ingredients such as colloidal oatmeal or calendula and follow approved monographs. If your product only moisturizes the skin without making therapeutic claims, it may be regulated as a cosmetic. 

Health Canada maintains a Natural Health Products Ingredients Database (NHPID) where you can verify whether your ingredients are permitted under the NHP framework: Visit the Health Canada NHPID to search ingredients and monographs. 

In the U.S., products that meet the conditions of an Over-the-Counter (OTC) Monograph, such as those containing hydrocortisone or colloidal oatmeal, may be marketed without pre-approval. If your product falls outside a monograph or makes new claims, you’ll need to file a New Drug Application (NDA). See the FDA’s OTC Drug Monograph Directory for reference. 

What you need to sell eczema products in Canada

If your eczema product is classified as an NHP, you must apply for a Natural Product Number (NPN) before selling it. This requires submitting detailed information about your product’s ingredients, claims, format, and recommended use. You’ll also need bilingual labelling and evidence of Good Manufacturing Practices (GMP). 

If your product is a cosmetic, you must submit a Cosmetic Notification Form (CNF) within 10 days of first sale in Canada. The formula must comply with the Cosmetic Ingredient Hotlist, and the label must list all ingredients in descending order of concentration. 

Some products fall into a grey area, especially if they include both moisturizing ingredients and therapeutic claims. We can help you determine the proper path to avoid compliance delays. 

What’s required in the U.S.

In the U.S., eczema treatments can be classified as OTC drugs or cosmetics, depending on claims and ingredients. For OTC drugs, you’ll need: 

  • An active ingredient listed in a final OTC monograph 
  • Drug Facts labeling format 
  • FDA establishment registration and product listing 
  • Manufacturing in a compliant facility 

If your product is a cosmetic only, it must follow the Modernization of Cosmetics Regulation Act (MoCRA), which includes registration and safety substantiation requirements. 

Trying to navigate these rules without proper guidance can lead to missteps and slow your time to market. 

Get it right the first time

Misclassifying your eczema product or making unapproved claims can result in: 

  • Refused submissions or delisting 
  • Warnings from regulators 
  • Product recalls or label changes 
  • Lost time and money 

That’s why it’s critical to classify your product correctly and align with all relevant compliance steps from the start. 

Support to streamline your compliance process

At Quality Smart Solutions, our team guides you through every stage of compliance. Whether you need help deciding if your product is an NHP or OTC drug, preparing an NPN application, or updating your Drug Facts label, we’re here to support you. 

We offer: 

  • Ingredient and product classification 
  • NPN application support 
  • Cosmetic notification filings 
  • OTC monograph compliance 
  • FDA and Health Canada label reviews 

And much more. 

Contact us or schedule a free consultation with one of our regulatory experts today to avoid costly mistakes and get your eczema product to market with confidence. 

Categories
Blog Cosmetics Regulatory Compliance

FDA vs Health Canada Cosmetic Compliance

Comparing FDA and Health Canada cosmetic compliance requirements

How FDA and Health Canada Regulate Cosmetics Differently 

Thinking about launching your cosmetic line in North America? Whether you’re a seasoned brand or just getting started, understanding FDA cosmetic compliance vs Health Canada requirements is a must. Each country has its own set of rules, and missing even one detail can cause delays, product holds, or costly corrections. 

This guide is here to help you stay ahead. We’ll break down how the FDA’s Modernization of Cosmetics Regulation Act (MoCRA) stacks up against Health Canada’s Cosmetic Regulations.  

If you’re working with skincare, makeup, or personal care products, you’ll find out exactly what it takes to meet the requirements on both sides of the border, and how to do it with confidence. 

What qualifies as a cosmetic? 

Before diving into compliance rules, it’s important to define what’s considered a cosmetic in each jurisdiction. 

  • Health Canada defines a cosmetic as any substance used to cleanse, improve, or alter the skin, hair, or teeth without affecting the body’s structure or functions. This includes makeup, moisturizers, and shampoos. 
  • The FDA shares a similar definition but draws a sharper line between cosmetics and drugs. Any product claiming to treat or prevent a medical condition (like acne or eczema) could fall under drug regulations instead. 

If you’re unsure whether your product is a cosmetic or something else, consult Health Canada’s Cosmetic or Drug Decision Tree or work with a regulatory expert. 

Regulatory filing: Who needs to be notified? 

One of the most notable differences between FDA and Health Canada compliance lies in mandatory submissions. 

  • In Canada, all cosmetic products must be notified to Health Canada within 10 days of sale through a Cosmetic Notification Form (CNF). This includes a complete ingredient list and company details. 
  • Under MoCRA, cosmetic companies in the U.S. must register their manufacturing facilities and list their products with the FDA. This became mandatory in 2023, marking a significant shift from the previous voluntary model. The FDA’s official page on MoCRA outlines these new requirements in detail. 

Failure to complete these steps can result in enforcement actions, product holds at the border, and reputational damage. 

Ingredient restrictions and safety substantiation 

When comparing FDA cosmetic compliance vs Health Canada, ingredient requirements are another key area to watch. 

  • Health Canada maintains a Cosmetic Ingredient Hotlist, which outlines prohibited or restricted substances. Products must not contain any ingredients that pose health risks or violate this list. 
  • The FDA does not publish a similar hotlist, but MoCRA now requires companies to maintain safety substantiation. This means you must have evidence showing your cosmetic product is safe under its intended use. 

In both markets, you need to verify that ingredients comply with each jurisdiction’s requirements, including allergens, preservatives, and colourants. 

Labeling requirements: Canadian bilingual rules vs U.S. warnings 

Labeling is one of the most common compliance pitfalls. It’s also an area where Canada and the U.S. diverge quite a bit. 

  • Health Canada mandates bilingual labeling (English and French) on all cosmetic packaging, along with INCI ingredient names, product function, and net quantity. 
  • FDA labeling requirements under MoCRA include ingredient lists, product identity, and a responsible person’s contact information. You’ll also need to comply with new fragrance allergen disclosures, expected in future rulemaking. 

Make sure your artwork is reviewed by someone who understands these regional requirements, especially if you’re using the same packaging for both countries. 

Responsible party and accountability 

Under MoCRA, the U.S. now requires each cosmetic to identify a responsible person, typically the brand owner or manufacturer. This person must maintain safety records and submit product listings. 

Canada doesn’t currently have an equivalent rule, but you must still provide accurate contact information for the party responsible for the sale of the product in Canada. If you’re an international brand entering the Canadian market, this may require partnering with a Canadian Cosmetic Agent. 

Enforcement and penalties 

While enforcement has historically been more reactive than proactive in both countries, MoCRA has introduced more structured oversight. 

  • In the U.S., the FDA can now issue mandatory recalls, suspend facility registrations, and conduct inspections with more authority. 
  • In Canada, Health Canada can take enforcement action if a product is found to be non-compliant or if consumer complaints arise. This could include product seizures or public safety alerts. 

Staying proactive with your compliance can help you avoid penalties and product disruptions in both regions. 

How to enhance your compliance strategy 

Whether you’re launching a new cosmetic brand or expanding into the U.S. or Canadian market, understanding the key differences between FDA cosmetic compliance vs Health Canada is essential. 

At Quality Smart Solutions, our regulatory experts can support your team with: 

  • MoCRA facility registration and product listings 
  • Health Canada Cosmetic Notification Form submissions 
  • Ingredient and formula assessments 
  • Bilingual label reviews and compliance 
  • Ongoing regulatory monitoring and updates 

We simplify the regulatory process so you can focus on building your brand. Contact us today or fill out the form below for a free consultation. 

Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.